Physician profile
Ann E Ayres
NPI 1922397041
$10,367.38
in general payments reported to CMS, 2019-2025
22 companies · $3,249 in 2025
The $3,249 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,296 · 2022: $2,213 · 2023: $1,362 · 2024: $2,247 · 2025: $3,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,311 · Consulting Fee: $1,125 · Education: $407 · Travel and Lodging: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,310.66 |
| Consulting Fee | $1,125.00 |
| Education | $406.88 |
| Travel and Lodging | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,312.67 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $2,092.49 | 2021-2025 | |
| Lilly USA, LLC | $1,159.15 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $989.67 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $855.76 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $787.40 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $545.36 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $342.36 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $271.16 | 2024-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $191.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $185.13 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $140.16 | 2023-2025 | Zoryve |
| Almirall LLC | $133.97 | 2021-2025 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $108.62 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.96 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.35 | 2021-2024 | |
| Organon LLC | $43.27 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $40.32 | 2025 | Nemluvio |
| Incyte Corporation | $19.25 | 2023 | Opzelura |
| Dermavant Sciences, INC. | $19.25 | 2024 | Vtama |
| Genentech USA, INC. | $18.92 | 2021 | |
| Amgen INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Ayres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.